Premarket Biotech Digest – $NEOT receives new patent, $NBIO files IND, $TRPX inks sublicense deal
This is a list of all the trades we did in our newly-launched swing trading group over the last two months. In 2 months, our profit was 66.5% as reported by members who made successful trades.
If interested, go here to see the original intro - http://drkkd.com/swing-trading-room-the-details-are-here/
Endocyte Inc. ($ECYT) announced the results from a new research which showed the importance of its small molecule drug conjugates (SMDCs) in reducing the risk of excessive cytokine release in patients receiving CAR-T therapy. The research was conducted at Purdue University Center for Drug Discovery and it showed that the company’s bi-specific SMDC adaptors can control the rate and extent of CAR T-cell activation.
The news was received positively by the market. The company stock has lost over 26 percent of its value in the past 12 months. However, the stock has shown some signs of pullback in the recent past. The company recently announced its quarterly results. It reported a net loss of $11.1 million for the fourth quarter while its R&D expenses stood at $8.2 million.
Neothetics ($NEOT) stock showed a spike as the company announced receiving a new patents from the USPTO for its lead product candidate LIPO-202. This is the company’s eighth patent and it covers methods of using LIPO-202 and other agents for the reduction of fat accumulation. The patent will offer protection through fourth quarter of 2031.
The company stock jumped over 12 percent on the news, creating a new 52 weeks high of $2.59. The stock is now up 55 percent on Year to Date basis, while its 12 months gain stands at 190 percent. Neothetics had recently announced its fourth quarter results. The company reported a net loss of $2 million while its annual loss stood at $13 million.
Oncolytics Biotech ($ONCYF) announced positive results from a Phase 2 clinical trial assessing the combination of REOLYSIN and paclitaxel in patients with p53 mutation-positive metastatic breast cancer. The results showed that adding REOLYSIN to chemo extended median overall survival to 20.9 months compared to 10.4 months for paclitaxel alone. Oncolytics said that it plans to carry out a registration study in metastatic breast cancer with OS as the primary endpoint.
Nascent Biotech ($NBIO) announced that it has filed its Investigational New Drug application for pritumumab, with the FDA. The treatment is designed for deals with brain tumors and other cancers. The company plans to start clinical trials later this year.
Allergan ($AGN) announced results from a Phase 2 proof-of-concept clinical trial assessing BOTOX (onabotulinumtoxinA) in adult females with Major Depressive Disorder. The trial showed benefits but failed to achieve the overall numbers of statistical significance. The 30-unit dose beat placebo numerically, but failed to hit the primary endpoint of a statistically valid increase in MADRS score versus placebo at week 6. The 50-unit dose failed to beat placebo.
Karyopharm Therapeutics ($KPTI) announced that the FDA has lifted the partial clinical hold on clinical trials of lead product candidate selinexor. The partial hold was put in place on March 10 and was imposed due to incomplete information in the existing version of the investigator's brochure, including an incomplete list of selinexor-related serious adverse events. The partial hold leads to the halt in patient recruitment.
Jazz Pharmaceuticals ($JAZZ) announced that it has resolved its patent infringement litigation with Hikma Pharmaceuticals PLC . The dispute is related to Xyrem and related to Raxane Labs filing an Abbreviated New Drug Application seeking approval to market a generic version. Roxane has now been acquired by Hikma. The setttement provides for Hikma and subsidiary West-Ward Pharmaceuticals to sell a generic version of Xyrem starting from January 1, 2023 or earlier under certain circumstances. Jazz will receive royalty in this regard.
Therapix Biosciences ($TRPX) announced that it has signed a sublicensing deal with Hebrew University's Yissum Research Development Company. The collaboration provides for global exclusive rights to its nasal drug delivery technology for the nasal delivery of cannabinoids. The technology is designed to administer and to facilitate effective nasal absorption of tetrahydrocannabinol (THC), the active ingredient in the drugs being developed by Therapix.
Impact on Share Price
Piper Jaffray Companies
Neutral -> Overweight
Aclaris Therapeutics (ACRS)
AerCap Holdings (AER)
Overweight -> Equal Weight
Bank of America Corp
AFLAC Incorporated (AFL)
Underperform -> Neutral
Keefe, Bruyette & Woods
AGNC Investment Corp (AGNC)
Keefe, Bruyette & Woods
Assured Guaranty (AGO)
Akari Therapeutics PLC (AKTX)
Air Lease Corp (AL)
Overweight -> Equal Weight
Goldman Sachs Group
Advanced Micro Devices (AMD)
Robert W. Baird
Gainers (% price change) Last Trade Change Mkt Cap
Alere Inc ALR 43.43 +3.73 (9.40%) 3.74B
China Cord Blood Corp CO 6.87 +0.50 (7.85%) 501.53M
Community Health Systems CYH 9.01 +0.37 (4.28%) 1.02B
Impax Laboratories Inc IPXL 12.60 +0.45 (3.70%) 921.64M
Omeros Corporation OMER 16.18 +0.57 (3.65%) 700.52M
Losers (% price change)
NewLink Genetics Corp NLNK 17.88 -2.91 (-14.00%) 470.40M
Idera Pharmaceuticals Inc IDRA 2.21 -0.26 (-10.53%) 334.92M
Infinity Pharmaceuticals INFI 2.80 -0.31 (-9.97%) 141.19M
BioCryst Pharmaceuticals BCRX 7.51 -0.78 (-9.41%) 594.93M
ImmunoGen, Inc. IMGN 3.37 -0.34 (-9.16%) 278.61M
Most Actives (dollar volume)
Johnson & Johnson JNJ 124.80 +0.12 (0.10%) 338.29B
Acadia Healthcare Co. Inc ACHC 44.12 +0.25 (0.57%) 3.95B
Pfizer Inc. PFE 34.19 -0.15 (-0.44%) 204.20B
UnitedHealth Group Inc UNH 165.37 +0.40 (0.24%) 158.88B
Amgen, Inc. AMGN 162.24 -2.12 (-1.29%) 119.82B